Ceftaroline: A 5th generation cephalosporin for the treatment of
CAP and cSSTIs in the era of antimicrobial resistance
24 Jan 2019
Antimicrobial resistance has been recognized as a serious public health issue.
In an era of antimicrobial resistance, newer agents are urgently needed. Ceftaroline, a broad spectrum cephalosporin approved for the treatment of community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTI) is a step forward towards addressing this need. MIMS Anti-Infectives interviewed Dr Asok Kurup, an infectious disease physician practising at the Mount Elizabeth Medical Centre in Singapore, to provide some insights into the role of ceftaroline for the treatment of these conditions.
Related MIMS Drugs